Protagonist Therapeutics, Inc (PTGX): R&D Expense
$159.29M
Year ended 2025-12-31
$175.16M
Trailing 12 months to 2026-06-30
+8.1%
3-year compound annual growth
+16.4%
5-year compound annual growth
+29.7%
10-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $159.29M | +15.3% | 2026-02-25, From 2025-01-01 |
| 2024-12-31 | $138.13M | +15.0% | 2026-02-25, From 2024-01-01 |
| 2023-12-31 | $120.16M | -4.8% | 2026-02-25, From 2023-01-01 |
| 2022-12-31 | $126.22M | +0.2% | 2025-02-21, From 2022-01-01 |
| 2021-12-31 | $126.01M | +69.1% | 2024-02-27, From 2021-01-01 |
| 2020-12-31 | $74.51M | +14.6% | 2023-03-15, From 2020-01-01 |
| 2019-12-31 | $65.00M | +9.3% | 2022-02-28, From 2019-01-01 |
| 2018-12-31 | $59.50M | +28.8% | 2021-03-10, From 2018-01-01 |
| 2017-12-31 | $46.18M | +79.7% | 2020-03-10, From 2017-01-01 |
| 2016-12-31 | $25.70M | +117.3% | 2019-03-12, From 2016-01-01 |
| 2015-12-31 | $11.83M | +58.6% | 2018-03-07, From 2015-01-01 |
| 2014-12-31 | $7.46M | n/a | 2017-03-07, From 2014-01-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| Protagonist Therapeutics, Inc (PTGX) | 2025-12-31 | $159.29M | +15.3% |
| Septerna, Inc. (SEPN) | 2025-12-31 | $97.58M | +49.4% |
| Aquestive Therapeutics, Inc. (AQST) | 2025-12-31 | $17.19M | -15.2% |
| Cumberland Pharmaceuticals Inc (CPIX) | 2025-12-31 | $5.57M | +15.6% |
| Xilio Therapeutics, Inc. (XLO) | 2025-12-31 | $56.04M | +36.0% |
| Gossamer Bio, Inc. (GOSS) | 2025-12-31 | $174.09M | +25.7% |
| Wave Life Sciences, Inc. (WVE) | 2025-12-31 | $182.78M | +14.5% |
| Lexicon Pharmaceuticals, Inc. (LXRX) | 2025-12-31 | $61.12M | -27.7% |
| Biofrontera Inc. (BFRI) | 2025-12-31 | $3.72M | +78.0% |
Compare PTGX, SEPN, AQST, CPIX side by side · Screen every company in Pharmaceutical Preparations ↗